CN-122012343-A - Bifidobacterium animalis subspecies lactis WLP90 and application thereof in preparation of preparation for relieving obesity

CN122012343ACN 122012343 ACN122012343 ACN 122012343ACN-122012343-A

Abstract

The application belongs to the technical field of bifidobacterium animalis subspecies lactis, and particularly relates to bifidobacterium animalis subspecies lactis WLP90 and application thereof in preparation of an obesity relieving preparation. The bifidobacterium animalis subspecies have the performance of targeted inhibition of actinomycetes (Actinomyces israelii), enterobacter oncogenic (Enterobacter cancerogenus) and multi-vitamin soxakamium (Alloscardovia omnicolens), can effectively inhibit pancreatic lipase and stimulate intestinal cells to produce glucagon-like peptide-1, can effectively improve the symptoms of obese mice, and can be used for preparing preparations for relieving obesity.

Inventors

FANG SHUGUANG
LI LUYAO
ZHU MINGMING
Yang Lvzhu
CHEN KEKE

Assignees

武汉微康益生菌研究院有限公司

Dates

Publication Date: 20260512
Application Date: 20260324

Claims (10)

1. A strain of bifidobacterium animalis subspecies lactis WLP90 is the bifidobacterium animalis subspecies lactis (Bifidobacterium animalis subsp. Lactis) WLP90 with the preservation number of CGMCC NO. 33688.
2. A bacteriostatic formulation comprising a mixture of at least one or more of dead, live, inactivated, metazoan and fermentation broth of bifidobacterium animalis subspecies lactis WLP90 according to claim 1.
3. The bacteriostatic formulation according to claim 2, which is at least one selected from the group consisting of a bacteriostatic formulation of actinomyces chlamydia (Actinomyces israelii), a bacteriostatic formulation of enterobacter oncogenic (Enterobacter cancerogenus), and a bacteriostatic formulation of sevelophtalmia guanfaciens (Alloscardovia omnicolens).
4. A glucagon-like peptide-1 stimulator comprising at least one or more of dead, live, inactivated, metazoan, and fermentation broth of bifidobacterium animalis subspecies lactis WLP90 of claim 1.
5. A probiotic preparation for aiding in the reduction of liver fat deposition comprising a mixture of at least one or more of dead, live, inactivated, metazoan and fermentation broth of bifidobacterium animalis subspecies lactis WLP90 according to claim 1.
6. A probiotic preparation for reducing the abundance of intermittent flora in the intestinal tract comprising a mixture of at least one or more of dead, live, inactivated, metazoan and fermentation broth of bifidobacterium animalis subspecies lactis WLP90 according to claim 1.
7. A probiotic preparation for reducing the abundance of entero-like corynebacteria and Dubosiella bacteria comprising a mixture of at least one or more of dead, live, inactivated, metazoan and fermentation broth of bifidobacterium animalis subspecies lactis WLP90 according to claim 1.
8. A scientific formulation for reducing the abundance of intermittent flora in the intestinal tract of an experimental animal comprising a mixture of at least one or more of dead, live, inactivated, metazoan and fermentation broth of bifidobacterium animalis subspecies lactis WLP90 according to claim 1.
9. A scientific formulation for reducing the abundance of intestinal tract-like corynebacteria and Dubosiella bacteria in an experimental animal, comprising a mixture of at least one or more of dead, live, inactivated, metazoan, and fermentation broth of bifidobacterium animalis subspecies lactis WLP90 of claim 1.
10. Use of bifidobacterium animalis subspecies lactis WLP90 as claimed in claim 1, comprising: preparing a fermentation preparation of bifidobacterium animalis subspecies lactis WLP 90; Preparing a bacteriostasis preparation; Preparing an inhibitor of pancreatic lipase; Preparing a stimulator of glucagon-like peptide-1; preparing a probiotic preparation for assisting in reducing liver fat deposition; preparing a probiotic preparation for reducing the abundance of intermittent flora in the intestinal tract; Preparing a probiotic preparation that reduces the abundance of intestinal-like corynebacteria and Dubosiella bacteria; preparing scientific preparation for reducing intermittent flora abundance in intestinal tracts of experimental animals, and Preparing at least one scientific preparation for reducing the abundance of the alteromonas and Dubosiella bacteria in the intestinal tract of the experimental animal.

Description

Bifidobacterium animalis subspecies lactis WLP90 and application thereof in preparation of preparation for relieving obesity Technical Field The application belongs to the technical field of bifidobacterium animalis subspecies lactis, and particularly relates to bifidobacterium animalis subspecies lactis WLP90 and application thereof in preparation of an obesity relieving preparation. Background Bifidobacterium animalis subspecies (Bifidobacterium animalis subsp. Lactis) are used as star strains in the field of probiotics, and are one of the most widely applied probiotic strains in foods, health-care products and pharmaceutical preparations by virtue of excellent gastrointestinal tract tolerance (gastric acid resistance and bile resistance), intestinal tract colonization potential and broad-spectrum physiological activity. A large number of researches prove that the strain has irreplaceable advantages in the aspects of regulating intestinal flora balance, improving metabolic disorder, enhancing immune function and the like. Diabetes is a global chronic metabolic disease characterized by hyperglycemia, the pathogenesis of which is mainly due to islet cell dysfunction such as insufficient or abnormal insulin secretion. Long-term work and rest is irregular, and diabetes mellitus can be caused by eating habits of high oil and high water, long-time sitting and no exercise. The persistent hyperglycemia of the human body often causes damage to other organs of the body, resulting in complications such as diabetic retinopathy, diabetic nephropathy, diabetic foot, and the like. Studies have shown that there is a causal relationship between intestinal flora imbalance and type II diabetes. Therefore, maintaining the health of the intestinal flora is of great importance for the management of diabetes. Probiotics are active microorganisms that the body supplements for ingestion, and the core function is to maintain or restore the balance of microbiota in the gut. Bifidobacterium animalis subspecies lactis (Bifidobacterium animalis subsp. Lactis) is a gram-positive class of bacilli that is found predominantly in breast milk and infant feces and gradually diminishes or even disappears in abundance with age. Plays an important probiotic function in human body. There are few types of bifidobacterium animalis subspecies that are currently available on the market that can safely and effectively reduce blood glucose and improve diabetes, and therefore, there is a need in the art to develop more bifidobacterium animalis subspecies that have a hypoglycemic potential. Disclosure of Invention The application provides a bifidobacterium animalis subspecies lactis WLP90, which is the bifidobacterium animalis subspecies lactis (Bifidobacterium animalis subsp. Lactis) WLP90 with the preservation number of CGMCC No. 33688. The application provides a bacteriostatic preparation which comprises a mixture of at least one or more of dead thalli, living thalli, inactivated thalli, metazoan and fermentation broth of animal bifidobacterium subspecies lactis WLP90 with the preservation number of CGMCC NO. 33688. The application provides a glucagon-like peptide-1 stimulator, which comprises at least one or a mixture of a plurality of dead thalli, living thalli, inactivated thalli, metazoan and fermentation liquor of animal bifidobacterium subspecies lactis WLP90 with the preservation number of CGMCC NO. 33688. The application provides a probiotic preparation for assisting in reducing liver fat deposition, which comprises a mixture of at least one or more of dead thalli, living thalli, inactivated thalli, metazoan and fermentation liquor of bifidobacterium animalis subspecies lactis WLP90 with a preservation number of CGMCC NO. 33688. The application provides a probiotic preparation for reducing the abundance of intermittent flora in intestinal tracts, which comprises a mixture of at least one or more of dead thalli, living thalli, inactivated thalli, metazoan and fermentation liquor of bifidobacterium animalis subspecies lactis WLP90 with a preservation number of CGMCC NO. 33688. The application provides a probiotic preparation for reducing the abundance of intestinal canal-like corynebacteria and Dubosiella bacteria, which comprises at least one or a mixture of a plurality of dead bacteria, living bacteria, inactivated bacteria, metazoan and fermentation liquor of animal bifidobacterium subspecies lactis WLP90 with the preservation number of CGMCC NO. 33688. The application provides a scientific preparation for reducing the abundance of intermittent flora in the intestinal tract of an experimental animal, which comprises a mixture of at least one or more of dead thalli, living thalli, inactivated thalli, metazoan and fermentation liquor of bifidobacterium animalis subspecies lactis WLP90 with a preservation number of CGMCC NO. 33688. The application provides a scientific preparation for reducing the intestinal canal sample corynebacterium abundan